Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

ed monthly and reviewed by the Company's

management and are presented quarterly to the Board.

Historically, funding for the Company's plan is primarily managed through

the issuance of additional common shares and common share purchase

warrants that upon exercise are converted to common shares. Management

regularly monitors the capital markets attempting to balance the timing

of issuing additional equity with the Company's progress through its

clinical trial program, general market conditions, and the availability

of capital. There are no assurances that funds will be made available to

the Company when required.

The Company is not subject to externally imposed capital requirements.

7. SHORT-TERM INVESTMENTS

Short-term investments, consisting of bankers' acceptances, are liquid

investments that are readily convertible to known amounts of cash and are

subject to an insignificant risk of changes in value. The objectives for

holding short-term investments are to invest the Company's excess cash

resources in investment vehicles that provide a better rate of return

compared to the Company's interest bearing bank account with limited risk

to the principal invested. The Company also intends to match the

maturities of these short-term investments with the cash requirements of

the Company's activities. The Company does not hold any asset backed

commercial paper.

Effective

Original Accrued Carrying Fair Interest

Cost Interest Value Value Rate

$ $ $ $

-------------------------------------------------------------------------

March 31, 2008

Short-term

investments 14,576,744 59,176 14,635,920 14,539,205 2
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... May 27, 2015 Expanding in a ... manufacturer Avalon Biomed Inc. recently inked a ... Mokuda Dental Co. Ltd. , the largest endodontic distributor ... the international market for Avalon Biomed, which manufactures Grey ... tricalcium silicate-based dental cements that have won renown from ...
(Date:5/27/2015)... SAN FRANCISCO, Calif. , May 27, 2015 ... for the treatment of cancer, today announced the ... financial officer and Cynthia Ladd as ... joining CytomX, Goeltz was chief financial officer of ... served as an independent consultant and legal counsel ...
(Date:5/27/2015)... , May 27, 2015  RXi Pharmaceuticals ... focused on discovering and developing innovative therapies primarily ... an update on the status of the Company,s ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... 3,085 and 21 shares of Series A Preferred ...
(Date:5/26/2015)... WORMS, GERMANY (PRWEB) May 26, 2015 ... W. R. Grace & Co. (NYSE: GRA) announces ... received good manufacturing practice (GMP) certification from EXCiPACTâ„¢, ... distributors of pharmaceutical excipients. , All ... brand of pharmaceutical grade excipient silica gels have ...
Breaking Biology Technology:Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 2Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 3CytomX Expands Executive Leadership Team 2CytomX Expands Executive Leadership Team 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2
... data presented today studied the safety of the ... to patients being evaluated for cardiac transplant.  GeNO ... development-stage technology company, announced that a study of ... (RHC) in subjects being evaluated for Orthotopic Heart ...
... Spain, April 19, 2012 Exciting new ... shows the gut microbiota,s causal role in the development ... of obesity [ 1] . Though an early ... of preventing diabetes and NAFLD with gut microbiota transplantation ...
... The longstanding mystery of how selective hearing works how ... out their crowded, noisy environs is solved this week ... the University of California, San Francisco (UCSF). Psychologists have ... name that evokes the Mad Men era in which it ...
Cached Biology Technology:New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 2New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 3New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation 4Gut Microbiota Transplantation may Prevent Development of Diabetes and Fatty Liver Disease 2Gut Microbiota Transplantation may Prevent Development of Diabetes and Fatty Liver Disease 3How selective hearing works in the brain 2How selective hearing works in the brain 3
(Date:5/21/2015)... -- According to a new market ... Services), by Applications (Surveillance (Airborne, Maritime, Land), Threat ... & Defense & Commercial) - Global Forecast to ... expected to grow from $7252.0 Million in 2015 ... Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/20/2015)... 2015 Research ... the addition of the  "5-year Opportunity ... Market"  report to their offering.  ,     ... analyses trends in the iris recognition ... sectors, globally. Despite hardware pricing and ...
(Date:5/19/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... many serious diseases remain a mystery? In considering that ... School of Medicine has come up with a unified molecular ... may provide an answer. Reviewing findings from multiple ... and Molecular Medicine and Investigator with the Howard Hughes Medical ...
... Ill. (Sept. 3, 2008) Scientists at the U.S. ... an $800,000 EUREKA award from the National Institutes of ... for measuring distances within a protein. ... Medium Angle X-ray solution scattering, would not only dramatically ...
... MADISON, WI, SEPTEMBER 2, 2008 Varying the rate of ... intuitive sense, as farmers have long observed differences in ... The availability of spatial yield information from combines equipped ... improved management. So, optimizing inputs to match ...
Cached Biology News:Do 68 molecules hold the key to understanding disease? 2NIH awards Argonne $800,000 to develop tool to measure distances within proteins 2A little nitrogen can go a long way 2A little nitrogen can go a long way 3
... (phospho S207) ( Abpromise for ... Antigen: Synthetic phosphopeptide derived from ... of Serine 207 (V-D-S P -V-A). ... 5608 Swiss ...
Rabbit polyclonal to Reptin/TIP49B/RUVB2 ( Abpromise for all tested applications). Antigen: Synthetic peptide (Human) Entrez Gene ID: 10856 Swiss Protein ID: Q6FIB9...
Mouse monoclonal [1Q17] to TGE Virus peplomer ( Abpromise for all tested applications)....
Goat polyclonal to ORC2L ( Abpromise for all tested applications). entrezGeneID: 4999 SwissProtID: Q13416...
Biology Products: